

# Concentrations of Oligosaccharides in Human Milk and Child Growth

**Philipp Menzel**

Leipzig University

**Mandy Vogel** (✉ [mandy.vogel@medizin.uni-leipzig.de](mailto:mandy.vogel@medizin.uni-leipzig.de))

Leipzig University

**Sean Austin**

Nestlé Research

**Norbert Sprenger**

Nestlé Research

**Nico Grafe**

Leipzig University

**Cornelia Hilbert**

Leipzig University

**Anne Jurkutat**

Leipzig University

**Wieland Kiess**

Leipzig University

**Aristea Binia**

Nestlé Research

---

## Research Article

**Keywords:** Children, Growth, Human Milk Oligosaccharides, HMO, Secretor Status, FUT2

**Posted Date:** April 13th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-403458/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

**Background:** The relationship between human milk oligosaccharides (HMO) and child growth has been investigated only insufficiently with ambiguous results. Therefore, this study examines potential influencing factors of HMO concentrations and how HMOs are associated with child growth parameters.

**Methods:** Milk samples from the German LIFE Child cohort of healthy children were analyzed for 9 HMOs. Putative associations with maternal and child cofactors and child height, head circumference and BMI between three months and seven years of age were examined. Secretor status, defined as the presence of 2'-fucosyllactose, was investigated for associations with infant outcomes.

**Results:** Our population consisted of 21 (14.7%) non-secretor and 122 (85.3%) secretor mothers. Maternal age was significantly associated with higher 3'SL concentrations; gestational age was associated with LNT, 6'SL and LNFP-I. Pre-pregnancy BMI was negatively associated with LNnT only in non-secretors. The growth velocity of non-secretors' children was inversely associated with LNnT at 3 months to 1 year ( $R=0.95$  [0.90, 0.99],  $p=0.014$ ), 1 to 2 years ( $R=0.80$  [0.72, 0.88],  $p<0.001$ ) and 5 to 6 years ( $R=0.71$  [0.57, 0.87],  $p=0.002$ ). 2'FL was negatively associated with BMI consistently, reaching statistical significance at 3 months and 4 and 5 years. Children of non-secretors showed higher BMI at 3 months, 6 months, and 3, 6, and 7 years of age.

**Conclusion:** We found that some associations between HMOs and infant growth may extend beyond the infancy and breastfeeding periods. They highlight the importance of both maternal and infant parameters in the understanding of the underlying associations.

**Trial registration:** The study is registered with ClinicalTrial.gov: NCT02550236.

## Introduction

Human milk is being explored intensively to understand its composition and physiological role for the breastfed infant. Lipids (1,2) have been identified as the most significant source of energy in mature milk. Additional important compounds of human milk are proteins, including enzymes and bioactive proteins like antibodies, nitrogenous compounds, and especially nucleotides, which influence the enzyme activity and the functionality of the immune system, hormones, vitamins, water and carbohydrates, including lactose and oligosaccharides. Together with lipids, lactose is an important source of energy, especially for the developing human brain (3). HMOs form the third largest solid fraction in human milk; they represent about 20% of the total carbohydrates, with an estimated amount of up to 20g/L in colostrum (4,5). HMOs are composed of 5 different monosaccharides (Glc, GlcNAc, Gal, Fuc and Neu5Ac), which are linked together via glycosidic bonds (6) to produce a wide variety of different structures (7).

HMO concentrations are influenced by lactation stage and maternal genetic factors (8–11) and probably to a lesser extent by maternal weight and body mass index (BMI) before pregnancy (8,9,12). HMOs have been investigated for their potential role in the early growth of neonates; however, their effects in early

and later metabolic health are unclear (13–19). To date, only one study has investigated the effects of HMOs on growth parameters beyond infancy (17). The possible underlying biochemical or physiological processes linking HMOs and infant growth are not understood. HMOs are indigestible but can be fermented at least partly by the infant's microbiome (20–22). Thus, they support the maturation of the gastrointestinal tract and the immune system and can protect against the colonization of pathogenic microorganisms by inhibiting their anchoring to human epithelial cells (12,23–25). In preclinical models, various studies have examined the effects of HMOs (sometimes combined with microbiota) on gut epithelial maturation, differentiation and signaling processes (26–28), which can affect nutrient uptake and developmental programming, as exemplified by their effects on bone formation (29). These preliminary observations suggest a potential role of HMOs and microbiota on infant growth.

In this study, we examine the association between maternal factors (maternal age, pre-pregnancy BMI) and the child's birth parameters (anthropometric measurements, gestational age (GA)) and the oligosaccharide composition in breast milk at 3 months postpartum. We also hypothesize associations between HMO concentrations and the child's anthropometric measurements (height, growth velocity, head circumference (HC), BMI) up to 7 years of age.

## Methods

### Study Design and Participants

All data were collected within the LIFE Child study at the Research Centre for Civilization Diseases in Leipzig, Germany ([www.ClinicalTrials.gov](http://www.ClinicalTrials.gov): NCT02550236). Children and their parents are recruited from the 24<sup>th</sup> week of gestation to 16 years of age to investigate environmental, metabolic and genetic associations with children's development (30). The study is described in detail elsewhere (30,31).

Between 2011 and 2014, 155 milk samples were collected from 153 nursing mothers at the 3-month baseline visit (Figure 1). The 3-month-visit took place after their 2<sup>nd</sup> full month and before the end of the 1<sup>st</sup> week of their 4<sup>th</sup> month of life. We excluded one sample because of a twin pregnancy and 9 samples because of preterm birth. Two mothers contributing two pregnancies were included. Finally, 145 sample-children combinations were included. Further, 132 follow-up measurements were documented at 6 months, 122 at 1 year, 106 at 2 years, 104 at 3 years, 90 at 4 years, 87 at five years, 59 at 6 years, and 37 at 7 years of age.

Informed written consent was provided by all parents for their children. The study has been conducted per the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of the Medical Faculty of the University of Leipzig (Reg. No. 264-10-19042010).

### Milk Collection, Storage and Analysis

Under private conditions, about 20mL of milk was collected at the 3-month visit using a milk pump (Medela Symphony®). The milk was stored without processing at -80°C at our biobank (30) until its

transport to Nestlé Research, Lausanne, on dry ice. The concentrations of 9 HMOs were determined by liquid chromatography (32): 2'-fucosyllactose (2'FL), 3-fucosyllactose (3-FL), 3'-sialyllactose (3'SL), 6'-sialyllactose (6'SL), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-fucopentaose-I (LNFP-I), lacto-N-fucopentaose-V (LNFP-V) and lacto-N-neofucopentaose (LNnFP).

## Measurements

Maternal pre-pregnancy weight and height and the child's birth parameters were taken from the maternity log ("Mutterpass"). This booklet is updated by medical staff during pregnancy checkups.

Measurements were taken by trained research assistants according to standard procedures.

Height/length was measured using the Dr. Keller II infantometer until one year of age and the Dr. Keller I stadiometer afterward. Weight was determined by using a scale (the seca 757 or the seca 701). HC was measured using non-dilatable measuring tape. BMI was calculated. Height/length, weight, and BMI were transformed to standard deviation scores (SDS) according to the guidelines from the German Working Group on Obesity in Childhood and Adolescence (33). HC measurements were transformed to SDS using German standards from the KiGGS study (34). As a measure of growth, growth velocity was calculated as the standardized difference between the three-month and the one-year measurement and afterward between two consecutive height measures.

## Statistical Analysis

All statistical analysis were carried out using R 4.0 (35). Descriptive statistics were given as median [min, max] for HMOs and mean (standard deviation) for the other continuous variables (Table 1). Correlations ( $r$ ) between the HMOs were investigated using Pearson correlations on the log-transformed values. Secretor status was determined based on the 2'FL concentration, with values of  $\leq 53\text{mg/L}$  corresponding to non-secretors and  $>53\text{mg/L}$  corresponding to secretors. Differences in means were tested using t-tests. For HMOs, differences in medians were tested using Kruskal-Wallis tests or censored regression models when data below the limit of quantification (LoQ) occurred. Values below the LoQ were set to the LoQ and marked as left censored. Chi-squared tests were applied to test differences in proportions. The associations between the HMOs and anthropometric and maternal parameters were examined using generalized additive models for location, shape, and scale (36,37), with HMO as the outcome and the other variables as predictor variables. Modeling was done separately for each age group, assuming a log-linear relationship between predictor and outcome. Due to the HMO values' considerable skewness, these values were log-transformed. A Box-Cox Cole and Green distribution or its censored equivalent was chosen to describe the outcomes' distributions. Investigating the models' error structure revealed variances according to secretor status. Therefore, variance was modeled dependent on secretor status. Skewness was dependent on secretor status only for LNnT. With evidence of an interaction between the predictor and the secretor status, the respective interaction term was included in the model. The models' appropriateness was checked using different plots (QQ-plot, variance against fitted, variance against covariates, influence vs. cooks distance; plots not shown). Effects are reported as ratios ( $R=\exp(\beta)$ ) or differences ( $\beta$ ), including the 95% confidence interval. As non-secretors values of LNFP-I and 2'FL were

below the LoQ ( $\leq 15\text{mg/L}$  and  $53\text{mg/L}$ , respectively) (32), associations involving LNFP-I and 2'FL were only modeled in the secretor subgroup. P-values  $\leq 0.05$  were considered to be statistically significant. Essentially, we concentrate on occurring patterns instead of single significant test results.

**Table 1.** Descriptive statistics of the cohort stratified by secretor group and overall given as median [min, max] for HMOs and mean (standard deviation) for the other continuous variables. Group differences were tested using Kruskal-Wallis-tests (HMOs) and t-tests (other variables).

	Secretor (n=124)	Non-secretor (n=21)	p- value	n=145	n missing) (non-
Maternal age	30.3 (4.12)	30.2 (4.95)	0.898	30.3 (4.24)	143
Pre-pregnancy BMI	23.2 (3.78)	22.7 (3.83)	0.642	23.2 (3.78)	124
Gestational age	40.0 (1.15)	40.2 (1.26)	0.494	40.0 (1.16)	145
Birth weight	3467 (473)	3646 (486)	0.13	3493 (477)	145
Birth length	50.3 (2.37)	50.7 (2.28)	0.475	50.4 (2.36)	144
Birth head circumference	34.9 (1.51)	35.3 (1.33)	0.301	35.0 (1.48)	123
HMOs					
2'FL	2038 [852;4719]	7.37 [3.90;32.2]	<0.001	1931 [3.90;4719]	145
3-FL	785 [7.59;2140]	2544 [299;3602]	<0.001	916 [7.59;3602]	145
3'SL	136 [75.2;388]	160 [75.8;274]	0.026	138 [75.2;388]	145
6'SL	151 [44.5;407]	139 [37.4;507]	0.39	150 [37.4;507]	145
LNT	547 [173;1830]	699 [338;1988]	0.01	567 [173;1988]	145
LNnT	149 [36.1;402]	66.9 [16.1;132]	<0.001	137 [16.1;402]	145
LNFP-I	473 [91.6;2372]	2.00 [2.00;6.43]	<0.001	416 [2.00;2372]	145
LNFP-V	44.6 [7.10;145]	197 [69.7;401]	<0.001	50.1 [7.10;401]	145
LNnFP	16.6 [5.60;69.1]	17.6 [5.60;50.9]	0.848	16.7 [5.60;69.1]	145

BMI, Body Mass Index; HMO, Human Milk Oligosaccharide; 2'FL, 2'-fucosyllactose; 3-FL, 3-fucosyllactose; 3'SL, 3'-sialyllactose; 6'SL, 6'-sialyllactose; LNT, lacto-N-tetraose; LNnT, lacto-N-neotetraose; LNFP-I, lacto-N-fucopentaose-I; LNFP-V, lacto-N-fucopentaose-V; LNnFP, lacto-N-neofucopentaose

## Results

### Descriptive Statistics and Correlations Between HMOs

The cohort consists of 21 (14.7%) non-secretor and 122 (85.3%) secretor mothers. Two of the secretor mothers took part with two singleton pregnancies (Figure 1). 2'FL, LNFP-I and LNnT concentrations were significantly lower in non-secretors, while 3-FL, 3'SL, LNT and LNFP-V concentrations were higher. Further descriptive statistics are given in Table 1.

Correlation was highest between 2'FL and LNFP-I ( $r=0.95$ ,  $p<0.001$ ). Both were also positively correlated to LNnT (2'FL:  $r=0.56$ ,  $p<0.001$ ; LNFP-I:  $r=0.61$ ,  $p<0.001$ ) and negatively correlated to LNFP-V (2'FL:  $r=-0.66$ ,  $p<0.001$ ; LNFP-I:  $r=-0.62$ ,  $p<0.001$ ) and 3-FL (2'FL:  $r=-0.54$ ,  $p<0.001$ ; LNFP-I:  $r=-0.64$ ,  $p<0.001$ ) (Figure 2).

### Maternal Parameters, Gestational Age and Birth Parameters

The maternal age at birth was positively associated only with 3'SL ( $R=1.06$  [1.00,1.11] for every five years older,  $p=0.03$ ). Pre-pregnancy BMI was negatively associated with LNnT in non-secretors ( $R=0.93$  [0.90,0.97],  $p<0.001$ ); no association was found in secretors. GA was positively associated with LNT ( $R=1.08$  [1.01,1.15],  $p=0.03$ ), 6'SL ( $R=1.09$  [1.03,1.16],  $p=0.005$ ) and LNFP-I ( $R=1.15$  [1.03,1.28],  $p=0.012$ , only secretors). LNFP-I ( $R=1.2$ , [1.05,1.37],  $p=0.008$ , only secretors) and 3-FL ( $R=0.92$  [0.86,0.98],  $p=0.011$ ) were significantly associated with birth length (Supplementary Table S1).

### Height-SDS and Growth Velocity

The interaction between height-SDS and secretor status was significant for LNT. The association of height-SDS with LNT had a negative direction in non-secretors ( $0.78 \leq R \leq 1.01$ ) and a positive direction in secretors ( $1.00 \leq R \leq 1.09$ ; Supplementary Table S2). However, the effects reached significance only in non-secretors at 2Y. LNFP-I was positively associated with height-SDS effects at 3M, 6M and 1Y ( $R \approx 1.2$ ,  $p \leq 0.02$ ); afterward, no further associations were found. Besides, there were consistently positive associations between height SDS and LNnT. However, statistical significance was only reached at 6Y. There was no evidence of associations between height-SDS and 2'FL, 3-FL, 3'SL, 6'SL, LNnFP, or LNFP-V.

The interaction between growth velocity and secretor status was significant for LNnT. In non-secretors, we found negative effects at 3M–1Y ( $R=0.95$  [0.90,0.99],  $p=0.01$ ), 1Y–2Y ( $R=0.80$  [0.72,0.88],  $p<0.001$ ) and in 5Y–6Y ( $R=0.71$  [0.57,0.87],  $p=0.002$ ).

LNT and LNFP-V were negatively associated with growth velocity from 3M–1Y (LNT:  $R=0.97$  [0.95,1.00],  $p=0.02$ ; LNFP-V:  $R=0.97$  [0.95,1.00],  $p=0.04$ ). LNFP-I and 3'SL were negatively associated with growth

velocity from LNFP-I: 1Y–2Y ( $R=0.90$  [0.83,0.97]  $p=0.008$ ) and 3'SL: 4Y–5Y ( $R=0.95$  [0.90,1.00]  $p=0.045$ ). No significant associations were found for growth velocity and 2'FL, 3-FL, 6'SL and LNnFP (Supplementary Table S3).

## BMI-SDS

The interaction between BMI-SDS and secretor status was significant for 3'SL, 6'SL, LNT, LNFP-V and LNnFP. For non-secretors, we found consistently negative associations between BMI-SDS and 3'SL, 6'SL, LNT and LNFP-V at all time points (Supplementary Table S4). However, statistical significance was reached only for LNT and LNFP-V at 2Y. Besides, we found consistently positive associations between BMI-SDS and LNnFP from 6M onward. Statistical significance was reached at 02Y, 05Y and 06Y. We did not find evidence of associations between BMI-SDS and the HMOs in secretors when the models included the interaction term.

2'FL showed consistently negative associations with BMI-SDS ( $0.92 \leq R \leq 1$ ; Supplementary Table S4); statistical significance was reached at 3M, 4Y and 5Y. The 3-FL was consistently positively associated with BMI-SDS between 3M and 6Y; however, the results did not reach statistical significance. For LNnT and LNFP-I, no consistent patterns were found.

## Head Circumference

The interaction between HC and secretor status was significant for LNFP-V and LNnFP. LNFP-V showed consistent, significantly negative associations with HC between 3M and 7Y, with effect sizes varying between 0.63 and 0.92 in non-secretors (Supplementary Table S5). Secretors had no notable pattern. LNnFP showed consistently positive effects on HC from 3M–7Y, with effect sizes between 1.12 and 2.09 in non-secretors. In general, the effect sizes increased with age. Statistical significance was reached from 2Y–6Y. Again, we found no notable patterns in secretors.

LNFP-I was consistently positively related to HC-SDS from 6M–7Y with effect sizes between 1.02 and 1.20. However, most of the effects did not reach significance. There were no notable pattern effects for 2'FL, 3-FL, 3'SL, 6'SL or LNT (Supplementary Table S5).

## Comparisons in Children of Non-secretors vs. Secretors

Children of non-secretor mothers had a significantly higher BMI-SDS at 3M ( $\beta=0.8$  [0.4,1.2],  $p<0.001$ ) and 6M ( $\beta=0.8$  [0.4,1.2],  $p<0.001$ ). At 1Y, the BMI-SDS was still 0.4 [-0.1,1.0] higher in children of non-secretors, but the effect did not reach significance ( $p=0.1$ ). At 2Y, there was no difference in BMI-SDS between both groups. Afterward, the non-secretor group had consistently higher mean BMI-SDS, reaching significance at 3Y and 7Y (Figure 3).

At 3M and 6M, non-secretor children showed a higher height-SDS (3M:  $\beta=0.5$  [-0.14,1.05; 6M:  $\beta=0.4$  [-0.09,0.94]),  $\beta=0.4$ ). However, the effect was not significant ( $p=0.1$ ). HC-SDS was astoundingly higher in non-secretors at 3M ( $\beta=1.3$  [0.6,2.0],  $p<0.001$ ), 6M ( $\beta=1.0$  [0.4,1.6],  $p=0.001$ ), and 1Y ( $\beta=0.7$  [0.3,1.2],

$p=0.002$ ). Even afterwards, HC-SDS stayed higher in non-secretors with effect sizes between  $\beta=0.4$  and  $\beta=1.0$ , reaching significance at 3Y, 6Y, and 7Y (Figure 3).

## Discussion

HMOs are indigestible but can be fermented, at least partially, by the infant's microbiome (20–23,38–40). This promotes the growth and activity of commensal bacteria such as *Bifidobacterium* and *Bacteroides spp.* and supports the gastrointestinal tract's maturation and the immune system (41). HMOs may also reduce the risk of infections by protecting against colonization with pathogenic microorganisms. It is proposed that they can act as decoys, inhibiting the pathogen anchoring to the human epithelial cells (24,25,42,43).

Recent studies proposed that HMOs, besides their antimicrobial effects, may be involved in an infant's growth and development. Sialylated oligosaccharides may exert a microbiota-dependent promotion of anabolic function in animal models by increasing the nutrient's efficiency, promoting better growth and physical development (44,45). Given the HMO-microbiome interaction and the microbiome's proposed effect on nutrient efficiency, the HMO composition of breast milk may also affect the infant's growth. Previous studies (14,15,17–19) investigating associations between HMOs and infant growth obtained conflicting results. Alderete et al. identified associations between LNFP-I and lower infantile weight, but not with pre-pregnancy BMI (15). In contrast, more recent studies found 2'FL positively associated with both child growth and pre-pregnancy BMI (17,18). Other studies reported no associations between HMO composition or secretor status with child growth (14,19).

Despite the variability in results, two recent studies indicated a role of sialylated HMOs in infant growth considering maternal BMI (19,46). Binia et al. found moderate associations between HMOs and infant growth and body composition during the first 4 months of life in a cohort of predominantly healthy babies and mothers with normal BMI. They reported significant associations of higher growth rate during the 4 months of lactation with higher 3'SL, expressed as Area Under the Curve of HMO concentrations at all visits, a potentially better measure of HMO exposure. Saben et al. confirmed the positive association of several sialylated HMOs, including 3'SL but also total acidic HMOs with infant growth during the first 6 months of life, including also obese mothers. The growth and body composition of the healthy infants were independent of maternal pre-pregnancy BMI. Interestingly, Saben et al. used calculated milk and HMO intake and not only concentrations, an attempt again to better quantify exposure to HMOs. The study was limited to one single time-point of HMO quantification at 2 months. Both studies lacked the longer follow-up of infant growth, which could be a better indicator of future risk to obesity. Finally, neither of these two studies confirmed the previous observations by Lagström et al. (17) and Larsson et al. (18) on the positive association of 2'FL and the negative association of LNnT with infant growth.

Despite measuring HMOs only at 3 months postpartum, limiting insights on associations between growth and the changing HMO exposure over time, we could include growth data from birth until 7 years of age. Indeed, we found higher BMI and HC SDS in non-secretors' than secretors' infants. Although significance



was not achieved at all time points, the probability of only positive results is  $p < 0.002$ . Growth velocity but not BMI was inversely correlated with LNT at 3M–1Y and 1Y–2Y in non-secretors, supporting the findings from Lagström et al. (17). Regarding the association between infant growth and sialylated HMOs 3'SL and 6'SL, we found a negative association with BMI-SDS in non-secretors but not with growth velocity, as previously reported (19,46).

Included mothers had a mean BMI of 23.2 (3.78) kg/m<sup>2</sup> and a mean age of 30 years, similar to other studies' populations (19,46). In line with previous results, we found a negative association between pre-pregnancy BMI and LNT in non-secretors (17). However, other studies reported a positive or no association (8,9,46). This highlights the variability of reported HMO associations, reflecting possible differences in methods or non-measured confounders. Therefore, future studies examining HMOs' role in growth and metabolic health should consider maternal physiology and other human milk components, such as proteins and lipids.

One *in vivo* intervention study with sialylated oligosaccharides (45) did report growth recovery following treatment with sialylated oligosaccharides in animal models of undernutrition. Recent clinical studies testing infant formula containing HMO effect on growth and body composition showed no differences in infant growth and development at least during the first months of life (47,48). The conflicting reported results from recent observational data call for hypothesis-driven studies to test the specific role of groups rather than single HMOs in influencing early growth and composition.

## Conclusion

Our results suggest that associations between HMOs and infant growth may extend beyond the breastfeeding period and interventional studies are needed to elucidate their influence on infant weight, height and body composition. Our study also confirms the value of long-term follow-up of breastfed infants and the inclusion of both maternal and infant factors to understand the role of HMOs in growth and development.(8, 10)

## Abbreviations

HMO, Human Milk Oligosaccharide; 2'FL, 2'-fucosyllactose; 3-FL, 3-fucosyllactose; 3'SL, 3'-sialyllactose; 6'SL, 6'-sialyllactose; LNT, lacto-N-tetraose; LNT, lacto-N-neotetraose; LNFP-I, lacto-N-fucopentaose-I; LNFP-V, lacto-N-fucopentaose-V; LNFP, lacto-N-neofucopentaose; BMI, Body Mass Index; HC, Head Circumference; GA, Gestational Age; SDS, Standard Deviation Score; Glc, Glucose; GlcNAc, N-Acetylglucosamine; Gal, Galactose; Fuc, Fucose; Neu5Ac, N-Acetylneuraminic acid; LoQ, Limit of Quantification

## Declarations

**Ethics approval and consent to participate:** The study has been conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of the Medical Faculty of the University of Leipzig (Reg. No. 264-10-19042010). Informed written consent was provided by all parents for their children.

**Consent for publication:** Not applicable.

**Availability of data and materials:** The legal requirements and the given informed consent do not allow public sharing of the dataset. Interested researchers can contact the research data management of the Medical Faculty, University Leipzig: [rdm@medizin.uni-leipzig.de](mailto:rdm@medizin.uni-leipzig.de) for further information. The dataset ID is PV450.

**Competing interests:** Aristea Binia, Sean Austin and Norbert Sprenger are employees of Société des Produits Nestlé. All other authors declare no conflict of interest.

**Funding:** This publication is supported by LIFE, Leipzig Research Center for Civilization Diseases, University of Leipzig. LIFE is funded by means of the European Union, by means of the European Social Fund (ESF), by the European Regional Development Fund (ERDF), and by means of the Free State of Saxony within the framework of the excellence initiative.

**Authors' contributions:** WK and AB conceived of the presented idea. NG, AJ, and CH were in charge of study organization and data collection. AB, SA, and NS were in charge of HMO analyses. PM and MV performed the statistical analyses, interpreted the results, wrote the first draft of the manuscript, and designed the visualizations. All authors discussed and contributed to the manuscript. All authors reviewed the results and approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

**Acknowledgements:** The authors would like to thank all participants, the Life Child Study Investigators, and the Life Child colleagues for their advice.

## References

1. Koletzko B, Rodriguez-Palmero M, Demmelmair H, Fidler N, Jensen R, Sauerwald T. Physiological aspects of human milk lipids. *Early Human Development*. 2001 Nov 1;65:S3–18.
2. Demmelmair H, Koletzko B. Lipids in human milk. *Best Practice & Research Clinical Endocrinology & Metabolism*. 2018 Jan 1;32(1):57–68.
3. Truchet S, Honvo-Houéto E. Physiology of milk secretion. *Best Practice & Research Clinical Endocrinology & Metabolism*. 2017 Aug 1;31(4):367–84.
4. Urashima T, Asakuma S, Leo F, Fukuda K, Messer M, Oftedal OT. The Predominance of Type I Oligosaccharides Is a Feature Specific to Human Breast Milk<sup>123</sup>. *Adv Nutr*. 2012 May 4;3(3):473S–482S.


5. Kunz C, Meyer C, Collado M, Geiger L, García-Mantrana I, Bertua-Ríos B, et al. Influence of Gestational Age, Secretor, and Lewis Blood Group Status on the Oligosaccharide Content of Human Milk. *Journal of Pediatric Gastroenterology and Nutrition*. 2017 May 1;64(5):789–98.
6. International Union of Pure and Applied Chemistry, editor. *Compendium of Chemical Terminology - Gold Book*. 2014.
7. Urashima T, Hirabayashi J, Sato S, Kobata A. Human Milk Oligosaccharides as Essential Tools for Basic and Application Studies on Galectins. *Trends in Glycoscience and Glycotechnology*. 2018;30(172):SE51–65.
8. Azad MB, Robertson B, Atakora F, Becker AB, Subbarao P, Moraes TJ, et al. Human Milk Oligosaccharide Concentrations Are Associated with Multiple Fixed and Modifiable Maternal Characteristics, Environmental Factors, and Feeding Practices. *J Nutr*. 2018 01;148(11):1733–42.
9. Samuel TM, Binia A, de Castro CA, Thakkar SK, Billeaud C, Agosti M, et al. Impact of maternal characteristics on human milk oligosaccharide composition over the first 4 months of lactation in a cohort of healthy European mothers. *Sci Rep* [Internet]. 2019 Aug 13 [cited 2020 Mar 16];9. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692355/>
10. Coppa GV, Gabrielli O, Pierani P, Catassi C, Carlucci A, Giorgi PL. Changes in carbohydrate composition in human milk over 4 months of lactation. *Pediatrics*. 1993 Mar;91(3):637–41.
11. Lefebvre G, Shevlyakova M, Charpagne A, Marquis J, Vogel M, Kirsten T, et al. Time of Lactation and Maternal Fucosyltransferase Genetic Polymorphisms Determine the Variability in Human Milk Oligosaccharides. *Front Nutr*. 2020;7:574459.
12. Bode L, Jantscher-Krenn E. Structure-Function Relationships of Human Milk Oligosaccharides123. *Adv Nutr*. 2012 May 4;3(3):383S-391S.
13. Maessen SE, Derraik JGB, Binia A, Cutfield WS. Perspective: Human Milk Oligosaccharides: Fuel for Childhood Obesity Prevention? *Adv Nutr* [Internet]. [cited 2019 Oct 22]; Available from: <https://academic.oup.com/advances/advance-article/doi/10.1093/advances/nmz093/5561598>
14. Sprenger N, Lee LY, De Castro CA, Steenhout P, Thakkar SK. Longitudinal change of selected human milk oligosaccharides and association to infants' growth, an observatory, single center, longitudinal cohort study. *PLoS One* [Internet]. 2017 Feb 9 [cited 2019 Feb 14];12(2). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300226/>
15. Alderete TL, Autran C, Brekke BE, Knight R, Bode L, Goran MI, et al. Associations between human milk oligosaccharides and infant body composition in the first 6 mo of life. *Am J Clin Nutr*. 2015 Dec 1;102(6):1381–8.
16. Dotz V, Rudloff S, Meyer C, Lochnit G, Kunz C. Metabolic fate of neutral human milk oligosaccharides in exclusively breast-fed infants. *Molecular Nutrition & Food Research*. 2015;59(2):355–64.
17. Lagström H, Rautava S, Ollila H, Kaljonen A, Turta O, Mäkelä J, et al. Associations between human milk oligosaccharides and growth in infancy and early childhood. *Am J Clin Nutr*. 2020 Feb 18;
18. Larsson MW, Lind MV, Laursen RP, Yonemitsu C, Larnkjær A, Mølgaard C, et al. Human Milk Oligosaccharide Composition Is Associated With Excessive Weight Gain During Exclusive

- Breastfeeding—An Explorative Study. *Front Pediatr* [Internet]. 2019 Jul 18 [cited 2020 Mar 31];7. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657391/>
19. Binia A, Lavalley L, Chen C, Austin S, Agosti M, Al-Jashi I, et al. Human milk oligosaccharides, infant growth, and adiposity over the first 4 months of lactation. *Pediatr Res*. 2021 Jan 14;
  20. Löffler G, Petrides PE, Heinrich PC. *Biochemie und Pathobiochemie*. 8., völlig neu bearb. Aufl. 2007. Heidelberg: Springer; 2006. 1266 p.
  21. Borewicz K, Gu F, Saccenti E, Arts ICW, Penders J, Thijs C, et al. Correlating Infant Fecal Microbiota Composition and Human Milk Oligosaccharide Consumption by Microbiota of 1-Month-Old Breastfed Infants. *Mol Nutr Food Res* [Internet]. 2019 Jul [cited 2020 Mar 16];63(13). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618098/>
  22. Walker WA, Iyengar RS. Breast milk, microbiota, and intestinal immune homeostasis. *Pediatr Res*. 2015 Jan;77(1–2):220–8.
  23. Ward RE, Niñonuevo M, Mills DA, Lebrilla CB, German JB. In Vitro Fermentation of Breast Milk Oligosaccharides by *Bifidobacterium infantis* and *Lactobacillus gasseri*. *Appl Environ Microbiol*. 2006 Jun;72(6):4497–9.
  24. Thai JD, Gregory KE. Bioactive Factors in Human Breast Milk Attenuate Intestinal Inflammation during Early Life. *Nutrients*. 2020 Feb;12(2):581.
  25. Coppa GV, Zampini L, Galeazzi T, Facinelli B, Ferrante L, Capretti R, et al. Human milk oligosaccharides inhibit the adhesion to Caco-2 cells of diarrheal pathogens: *Escherichia coli*, *Vibrio cholerae*, and *Salmonella typhi*. *Pediatr Res*. 2006 Mar;59(3):377–82.
  26. Kuntz S, Kunz C, Rudloff S. Oligosaccharides from human milk induce growth arrest via G2/M by influencing growth-related cell cycle genes in intestinal epithelial cells. *British Journal of Nutrition*. 2009 May;101(9):1306–15.
  27. Eiwegger T, Stahl B, Haidl P, Schmitt J, Boehm G, Dehlink E, et al. Prebiotic oligosaccharides: In vitro evidence for gastrointestinal epithelial transfer and immunomodulatory properties. *Pediatric Allergy and Immunology*. 2010 Dec 1;21(8):1179–88.
  28. Rudloff S, Stefan C, Pohlentz G, Kunz C. Detection of ligands for selectins in the oligosaccharide fraction of human milk. *Eur J Nutr*. 2002 Apr;41(2):85–92.
  29. Cowardin CA, Ahern PP, Kung VL, Hibberd MC, Cheng J, Guruge JL, et al. Mechanisms by which sialylated milk oligosaccharides impact bone biology in a gnotobiotic mouse model of infant undernutrition. *Proc Natl Acad Sci U S A*. 2019 Jun 11;116(24):11988–96.
  30. Quante M, Hesse M, Döhnert M, Fuchs M, Hirsch C, Sergeyev E, et al. The LIFE child study: a life course approach to disease and health. *BMC Public Health*. 2012 Nov 22;12:1021.
  31. Poulain T, Baber R, Vogel M, Pietzner D, Kirsten T, Jurkutat A, et al. The LIFE Child study: a population-based perinatal and pediatric cohort in Germany. *Eur J Epidemiol*. 2017 Feb 1;32(2):145–58.
  32. Austin S, De Castro CA, Bénet T, Hou Y, Sun H, Thakkar SK, et al. Temporal Change of the Content of 10 Oligosaccharides in the Milk of Chinese Urban Mothers. *Nutrients* [Internet]. 2016 Jun 8 [cited 2019 Mar 3];8(6). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924187/>

33. Wabitsch M, Kunze D. Konsensbasierte (S2) Leitlinie zur Diagnostik, Therapie und Prävention von Übergewicht und Adipositas im Kindes-und Jugendalter[Evidence-based therapy guideline of the German Working Group on Obesity in Childhood and Adolescence]. Version 15.10.2015; [www.a-g-a.de](http://www.a-g-a.de). :116.
34. Stolzenberg H, Kahl H, Bergmann KE. [Body measurements of children and adolescents in Germany. Results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007 Jun;50(5–6):659–69.
35. R Core Team. R: A language and environment for statistical computing. [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2020. Available from: <https://www.R-project.org/>
36. Stasinopoulos MD, Rigby RA, Bastiani FD. GAMLSS: A distributional regression approach. Statistical Modelling. 2018 Jun 1;18(3–4):248–73.
37. Stasinopoulos M, Rigby B, Mortan N. gamlss.cens: Fitting an Interval Response Variable Using ‘gamlss.family’ Distributions [Internet]. 2018 [cited 2021 Jan 31]. Available from: <https://CRAN.R-project.org/package=gamlss.cens>
38. Cabrera-Rubio R, Collado MC, Laitinen K, Salminen S, Isolauri E, Mira A. The human milk microbiome changes over lactation and is shaped by maternal weight and mode of delivery. Am J Clin Nutr. 2012 Sep 1;96(3):544–51.
39. Obermajer T, Lipoglavšek L, Tompa G, Treven P, Lorbeg PM, Matijašić BB, et al. Colostrum of Healthy Slovenian Mothers: Microbiota Composition and Bacteriocin Gene Prevalence. PLoS One [Internet]. 2015 Apr 28 [cited 2018 Sep 21];10(4). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412836/>
40. Martín R, Langa S, Reviriego C, Jiménez E, Marín ML, Xaus J, et al. Human milk is a source of lactic acid bacteria for the infant gut. The Journal of Pediatrics. 2003 Dec 1;143(6):754–8.
41. Jost T, Lacroix C, Braegger C, Chassard C. Impact of human milk bacteria and oligosaccharides on neonatal gut microbiota establishment and gut health. Nutr Rev. 2015 Jul 1;73(7):426–37.
42. Morrow AL, Ruiz-Palacios GM, Altaye M, Jiang X, Guerrero ML, Meinzen-Derr JK, et al. Human milk oligosaccharides are associated with protection against diarrhea in breast-fed infants. The Journal of Pediatrics. 2004 Sep 1;145(3):297–303.
43. Jiang X, Huang P, Zhong W, Tan M, Farkas T, Morrow AL, et al. Human Milk Contains Elements That Block Binding of Noroviruses to Human Histo–Blood Group Antigens in Saliva. The Journal of Infectious Diseases. 2004 Nov 15;190(10):1850–9.
44. Jumpertz R, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C, Gordon JI, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans<sup>123</sup>. Am J Clin Nutr. 2011 Jul;94(1):58–65.
45. Charbonneau MR, O'Donnell D, Blanton LV, Totten SM, Davis JCC, Barratt MJ, et al. Sialylated milk oligosaccharides promote microbiota-dependent growth in models of infant undernutrition. Cell. 2016 Feb 25;164(5):859.


46. Saben JL, Sims CR, Abraham A, Bode L, Andres A. Human Milk Oligosaccharide Concentrations and Infant Intakes Are Associated with Maternal Overweight and Obesity and Predict Infant Growth. *Nutrients*. 2021 Jan 29;13(2).
47. Puccio G, Alliet P, Cajozzo C, Janssens E, Corsello G, Sprenger N, et al. Effects of Infant Formula With Human Milk Oligosaccharides on Growth and Morbidity: A Randomized Multicenter Trial. *J Pediatr Gastroenterol Nutr*. 2017 Apr;64(4):624–31.
48. Marriage BJ, Buck RH, Goehring KC, Oliver JS, Williams JA. Infants Fed a Lower Calorie Formula With 2'FL Show Growth and 2'FL Uptake Like Breast-Fed Infants. *J Pediatr Gastroenterol Nutr*. 2015 Dec;61(6):649–58.

## Figures



**Figure 1**


Flow chart of the study design.



**Figure 2**

Correlogram of the log-transformed HMO values. Correlations coefficients, respective confidence intervals, and p-values are shown. HMO, Human Milk Oligosaccharide; 2'FL, 2'-fucosyllactose; 3-FL, 3-fucosyllactose; 3'SL, 3'-sialyllactose; 6'SL, 6'-sialyllactose; LNT, lacto-N-tetraose; LNnT, lacto-N-neotetraose; LNFP-I, lacto-N-fucopentaose-I; LNFP-V, lacto-N-fucopentaose-V; LNnFP, lacto-N-neofucopentaose.





**Figure 3**

Mean differences in BMI-SDS, HC-SDS, and Height-SDS between the secretor and non-secretor group and 95%-confidence intervals. Mean SDS-differences >0 represent higher values in non-secretors compared to secretors. From 3 months to 7 years of age BMI-SDS and HC-SDS were higher in non-secretors, especially at 3M, 6M, 01Y, and 03Y. Body Mass Index; HC, Head Circumference; SDS, Standard Deviation Score.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [AdditionalFileSupplementaryTableS1S5.docx](#)